<SEC-DOCUMENT>0001493152-22-029496.txt : 20221025
<SEC-HEADER>0001493152-22-029496.hdr.sgml : 20221025
<ACCEPTANCE-DATETIME>20221025113216
ACCESSION NUMBER:		0001493152-22-029496
CONFORMED SUBMISSION TYPE:	8-K
PUBLIC DOCUMENT COUNT:		3
CONFORMED PERIOD OF REPORT:	20221025
ITEM INFORMATION:		Other Events
ITEM INFORMATION:		Financial Statements and Exhibits
FILED AS OF DATE:		20221025
DATE AS OF CHANGE:		20221025

FILER:

	COMPANY DATA:	
		COMPANY CONFORMED NAME:			bioAffinity Technologies, Inc.
		CENTRAL INDEX KEY:			0001712762
		STANDARD INDUSTRIAL CLASSIFICATION:	SERVICES-COMMERCIAL PHYSICAL & BIOLOGICAL RESEARCH [8731]
		IRS NUMBER:				465211056
		STATE OF INCORPORATION:			DE
		FISCAL YEAR END:			1231

	FILING VALUES:
		FORM TYPE:		8-K
		SEC ACT:		1934 Act
		SEC FILE NUMBER:	001-41463
		FILM NUMBER:		221327873

	BUSINESS ADDRESS:	
		STREET 1:		22211 WEST INTERSTATE-10
		STREET 2:		SUITE 1206
		CITY:			SAN ANTONIO
		STATE:			TX
		ZIP:			78257
		BUSINESS PHONE:		210-698-5334

	MAIL ADDRESS:	
		STREET 1:		22211 WEST INTERSTATE-10
		STREET 2:		SUITE 1206
		CITY:			SAN ANTONIO
		STATE:			TX
		ZIP:			78257
</SEC-HEADER>
<DOCUMENT>
<TYPE>8-K
<SEQUENCE>1
<FILENAME>form8-k.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 4pt solid; border-bottom: Black 1.5pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>UNITED
STATES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>SECURITIES
AND EXCHANGE COMMISSION</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 12pt"><B>Washington,
D.C. 20549</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>FORM
8-K</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>CURRENT
REPORT</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to Section 13 or 15(d) of the Securities Exchange Act of 1934</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>October
25, 2022</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Date
of Report (Date of earliest event reported)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 18pt"><B>BIOAFFINITY
TECHNOLOGIES, INC.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Exact
name of registrant as specified in its charter)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Delaware</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>001-41463</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 32%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>46-5211056</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(State
    or other jurisdiction</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">of
    incorporation)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Commission</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">File
    Number)</FONT></P></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(I.R.S.
    Employer</FONT></P>
    <P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Identification
    Number)</FONT></P></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>22211
W Interstate 10</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Suite
1206</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>San
Antonio, Texas 78257</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>(210)
698-5334</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center; text-indent: 2.15pt"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(Address
of principal executive offices and Registrant&rsquo;s telephone number, including area code)</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Check
the appropriate box below if the Form 8-K filing is intended to simultaneously satisfy the filing obligation of the registrant under
any of the following provisions (see General Instruction A.2. below):</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.25in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Written
    communications pursuant to Rule 425 under the Securities Act (17 CFR 230.425)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Soliciting
    material pursuant to Rule 14a-12 under the Exchange Act (17 CFR 240.14a-12)</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 14d-2(b) under the Exchange Act (17 CFR 240.14d-2(b))</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&#9744;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pre-commencement
    communications pursuant to Rule 13e-4(c) under the Exchange Act (17 CFR 240.13e- 4(c))</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Indicate
by check mark whether the registrant is an emerging growth company as defined in Rule 405 of the Securities Act of 1933 (&sect;230.405
of this chapter) or Rule 12b-2 of the Securities Exchange Act of 1934 (&sect;240.12b-2 of this chapter).</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Emerging
growth company &#9746;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Title
    of each class</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 20%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Trading
    Symbol(s)</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 2%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 38%; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Name
    of each exchange on which registered</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Common
    Stock, par value $.007 per share</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAF</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Stock Market LLC</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tradeable
    Warrants to purchase Common Stock</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIAFW</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
    Nasdaq Stock Market LLC</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">If
an emerging growth company, indicate by check mark if the registrant has elected not to use the extended transition period for complying
with any new or revised financial accounting standards provided pursuant to Section 13(a) of the Exchange Act. &#9744;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Rule-Page --><DIV STYLE="width: 100%"><DIV STYLE="font-size: 1pt; border-top: Black 1.5pt solid; border-bottom: Black 4pt solid">&nbsp;</DIV></DIV><!-- Field: /Rule-Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
8.01. Other Events.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><U>Recent
Press Release</U></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">On
October 25, 2022, the Company issued a press releases announcing the award of patents in China, Mexico, and Australia. The press release
is filed as Exhibit 99.1 to this Form 8-K and is incorporated herein by reference.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Item
9.01 Financial Statements and Exhibits.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="text-align: justify; font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">(d)
<U>Exhibits</U>.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 0.75in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
    No.</B></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 0.1in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Description</B></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">99.1</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><A HREF="ex99-1.htm">Press Release of bioAffinity Technologies, Inc., dated October 25, 2022.</A></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 2 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin-top: 0pt; margin-bottom: 0pt; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>SIGNATURES</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; text-indent: 0.5in"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Pursuant
to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by
the undersigned hereunto duly authorized.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">BIOAFFINITY
    TECHNOLOGIES, INC.</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD COLSPAN="2" STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 50%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 3%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">By:</FONT></TD>
    <TD STYLE="border-bottom: black 1.5pt solid; font: 10pt Times New Roman, Times, Serif; width: 47%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><I>/s/
    Maria Zannes</I></FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
    Zannes</FONT></TD></TR>
  <TR STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">President
    and Chief Executive Officer</FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Dated:
October 25, 2022</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>


<!-- Field: Page; Sequence: 3; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>&nbsp;</B></FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>EX-99.1
<SEQUENCE>2
<FILENAME>ex99-1.htm
<TEXT>
<HTML>
<HEAD>
     <TITLE></TITLE>
</HEAD>
<BODY STYLE="font: 10pt Times New Roman, Times, Serif">

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: right"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Exhibit
99.1</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<TABLE CELLSPACING="0" CELLPADDING="0" STYLE="font: 10pt Times New Roman, Times, Serif; width: 100%; border-collapse: collapse">
  <TR STYLE="font: 10pt Times New Roman, Times, Serif">
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt; background-color: black"><IMG SRC="ex99-1_001.jpg" ALT="" STYLE="width: 264px; height: 109px"></FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; vertical-align: top; width: 2%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></TD>
    <TD STYLE="font: 10pt Times New Roman, Times, Serif; width: 49%"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>News
    Release</B></FONT></TD></TR>
  </TABLE>
<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>For
Immediate Release</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>bioAffinity
Technologies Announces Award of Therapeutic Patents in China, Mexico and Australia </B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: center"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B><I>Awarded
patents protect novel porphyrin conjugated compounds for selective delivery of cancer treatments</I></B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">SAN
ANTONIO, TX &ndash; Oct. 25, 2022 &ndash; bioAffinity Technologies, Inc. (NASDAQ: BIAF; BIAFW) announced the People&rsquo;s Republic
of China awarded a Certificate of Patent to the Company&rsquo;s wholly owned subsidiary OncoSelect<SUP>&reg;</SUP> for its patent &ldquo;<I>Porphyrin
Compounds and Compositions Useful for Treating Cancer</I>&rdquo; that is directed to novel compounds in which porphyrins are conjugated
to chemotherapeutics for selective delivery of cancer treatment.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies also announced that Mexico and Australia recently awarded the Company therapeutic patents with claims directed to novel
compounds of porphyrin conjugates for selective delivery of cancer treatment. The patents grant protection to 2037.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;An
estimated 4.5 million people are expected to receive a cancer diagnosis this year in China, and more than 3 million people are expected
to die. Cancer is the leading cause of death in China,&rdquo; said Maria Zannes, President and Chief Executive Officer of bioAffinity
Technologies. &ldquo;Nearly 200,000 Mexicans are diagnosed annually with cancer, and an estimated one in 18 Australians are expected
to have a personal history of cancer by 2040. The award of these patents in China, Mexico and Australia is further evidence that bioAffinity
Technologies can be a leader in advancing novel approaches for both diagnosing and treating this deadliest of diseases.<FONT STYLE="background-color: white">&rdquo;</FONT></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity&rsquo;s
therapeutic discoveries are the result of research related to advancing its non-invasive lung cancer diagnostic CyPath<SUP>&reg;</SUP>
Lung which has shown 92% sensitivity and 87% specificity in detecting lung cancer in people at high risk for the disease and who have
small nodules less than 20 millimeters. CyPath<SUP>&reg;</SUP> Lung uses a specific fluorescent porphyrin that labels cancer cells in
a patient&rsquo;s lung sputum sample for detection using flow cytometry. The intellectual property associated with CyPath<SUP>&reg;</SUP>
Lung was licensed and has been developed as a laboratory developed test by Precision Pathology Services for sale to physicians.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<!-- Field: Page; Sequence: 1 -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <DIV STYLE="break-before: page; margin-top: 6pt; margin-bottom: 0pt"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&ldquo;bioAffinity&rsquo;s
research led to an accurate, patient-friendly test to detect early-stage lung cancer. Our research also uncovered novel approaches being
developed to treat cancer. The selectivity of porphyrins for cancer makes them excellent candidates for drug delivery and diagnostic
products,&rdquo; Zannes said.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>



<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">The
Company and its subsidiary OncoSelect hold patents in the U.S., Australia, Canada, China, France, Germany, Hong Kong, Italy, Mexico,
Spain, Sweden, and the United Kingdom.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>About
bioAffinity Technologies, Inc.</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">bioAffinity
Technologies, Inc. (NASDAQ: BIAF; BIAFW) addresses the need for noninvasive diagnosis of early-stage cancer and diseases of the lung,
and targeted cancer treatment. The Company&rsquo;s first product, CyPath<SUP>&reg;</SUP> Lung, is a non-invasive test that has shown
high sensitivity and specificity for the detection of early-stage lung cancer. CyPath<SUP>&reg;</SUP> Lung is marketed as a Laboratory
Developed Test (LDT) by Precision Pathology Services. OncoSelect<SUP>&reg;</SUP> Therapeutics, LLC, a subsidiary of bioAffinity Technologies,
is advancing its discoveries shown <I>in vitro</I> to kill cancer cells without harm to normal cells. Research and optimization of the
Company&rsquo;s platform technologies are conducted in its laboratories at The University of Texas at San Antonio.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Forward-Looking
Statements</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify; background-color: white"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">This
press release contains forward-looking statements, including statements regarding the anticipated use of proceeds from the Company&rsquo;s
offering of common shares. Forward-looking statements can be identified by words such as &ldquo;believes,&rdquo; &ldquo;expects,&rdquo;
&ldquo;estimates,&rdquo; &ldquo;intends,&rdquo; &ldquo;may,&rdquo; &ldquo;plans,&rdquo; &ldquo;will&rdquo; and similar expressions, or
the negative of these words. Such forward-looking statements are based on facts and conditions as they exist at the time such statements
are made and predictions as to future facts and conditions. Readers of this press release are cautioned not to place undue reliance on
any forward-looking statements. The Company does not undertake any obligation to update any forward-looking statement relating to matters
discussed in this press release, except as may be required by applicable securities laws.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Contacts:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Company
Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Maria
Zannes, President &amp; Chief Executive Officer</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">mz@bioaffinitytech.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"><B>Investor
Relations Contact:</B></FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify">&nbsp;</P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Tiberend
Strategic Advisors, Inc.</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">Jonathan
Nugent</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">jnugent@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">or</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">David
Irish</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">dirish@tiberend.com</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt"></FONT></P>

<!-- Field: Page; Sequence: 2; Options: Last -->
    <DIV STYLE="margin-top: 0pt; margin-bottom: 6pt; border-bottom: Black 1.5pt solid"><TABLE CELLPADDING="0" CELLSPACING="0" STYLE="border-collapse: collapse; width: 100%; font-size: 10pt"><TR STYLE="vertical-align: top; text-align: left"><TD STYLE="width: 100%">&nbsp;</TD></TR></TABLE></DIV>
    <!-- Field: /Page -->

<P STYLE="font: 10pt Times New Roman, Times, Serif; margin: 0pt 0; text-align: justify"><FONT STYLE="font-family: Times New Roman, Times, Serif; font-size: 10pt">&nbsp;</FONT></P>

</BODY>
</HTML>
</TEXT>
</DOCUMENT>
<DOCUMENT>
<TYPE>GRAPHIC
<SEQUENCE>3
<FILENAME>ex99-1_001.jpg
<TEXT>
begin 644 ex99-1_001.jpg
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M 0$! 0$!         0(#! 4&!P@)"@O_Q "U$0 " 0($! ,$!P4$!  ! G<
M 0(#$00%(3$&$D%1!V%Q$R(R@0@40I&AL<$)(S-2\!5B<M$*%B0TX27Q%Q@9
M&B8G*"DJ-38W.#DZ0T1%1D=(24I35%565UA96F-D969G:&EJ<W1U=G=X>7J"
M@X2%AH>(B8J2DY25EI>8F9JBHZ2EIJ>HJ:JRL[2UMK>XN;K"P\3%QL?(R<K2
MT]35UM?8V=KBX^3EYN?HZ>KR\_3U]O?X^?K_V@ , P$  A$#$0 _ /U3HHHH
M **** "BBB@ HHHH **** "BBB@ HHHH **\:_:J^+FJ_!/X*:SXHT6U6ZU.
M)X;:V\Y=T<3RR!/,?V3-?.G[$_[67C[XI?$NZ\)>+KB'7(+BSFO(;V.U2%[9
MDV??\OY-C[^* /I3XY?M'>%/@!8V+:_]JN;Z^W_9M/L8]\SJGWWQGY4'K6]\
M(/C+X>^-WA,:[X=GE\E9##/;W2;)K>4?P.G;K7EG[5W[*\W[0C:+J.E:Q#I6
MMZ6KP!KM'>&6%OF(.SE3GO74?LS_  #7]GSP3<Z7-J2ZKJ=]<_:KRX1-D>[8
M$5$3L* /G/\ :N_:.^('A'XR7OAS0=8E\/:9I<,,D26\*;[G>F_>^_\ @_@_
MX!7UG\"?&>H>/?A'X8\0:O"D&H:A;>9*(TVHYWE=X'^WC?\ \#K4\6?"WP?X
M]NK:Y\1>'--UJZMO]3->6Z2.GXUTT%O':PI#$BQPHNU$1<*JT ?G#\5O$_Q#
MM_CAK<4E]K$&N1:E(FFVEH[\H7_<^2G]S9LK]"[&ZU"'PO;W-W;^9J:6:O-!
M'_%-L^9/^^JTVMX7F69HE\U?NN5^:K% 'PCX,_:.^(&H?$+3Y[G47N[>\O$A
M?1_*3R=COLV(?6OMOQ!X@LO#.C7FJ:A+Y-G:)YDLGH*SK;X>>&;'7I-<M]!T
M^#6'&&ODMU$GYTWQWX4MO'GA/4]#GF:&&\BV><G6-OO*X_&@#E?A[\?O#?Q%
MUJ32K)+JUO=C20I=Q[/.0=TKU"O ?A'^SC<_#_Q:FM:KJ\%]);;_ +-#:HR<
MN-N]ZZ3X\?$C4_ 6EZ8FCA([J^D=#<R)O"*@S_6@#UJBO)O@/\1]4\=:=J$.
MK[)KJQ=!]I1-@??[5ZS0 4444 %%%% !1110 44F:* %HHHH **2C- "T444
M %%%% !117Q)_P %.OBCXZ^&_@+PI#X3U&^T'2=2O9XM3U73GV.A5$,,._\
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MV S7YN?M@>*Q\9_CYIGA;PZWVP6)71X6A^=&N7?]Y_WQ\G_?#UIF-OJ_(<_
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ME?%/[ _[*>A?M&W_ (NU3QI!=7'A_2TAM8?LMT\#M>/\[G>G]Q,?]_*^QO\
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M)_J+G2]-A?\ W'GD2OT<_9C_ .3<_AG_ -B[8?\ HA*_._\ X*,?\GG^&_\
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*U%% !1110!__V0$!

end
</TEXT>
</DOCUMENT>
</SEC-DOCUMENT>
